NASDAQ:VSTM Verastem (VSTM) Stock Price, News & Analysis $4.08 +0.14 (+3.43%) As of 12:11 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Verastem Stock (NASDAQ:VSTM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Verastem alerts:Sign Up Key Stats Today's Range$3.94▼$4.1850-Day Range$3.62▼$6.5852-Week Range$3.55▼$11.24Volume574,454 shsAverage Volume2.08 million shsMarket Capitalization$358.07 millionP/E RatioN/ADividend YieldN/APrice Target$15.60Consensus RatingModerate Buy Company Overview Verastem Oncology, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept. The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S. Food and Drug Administration approval in 2018 for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma. In parallel, Verastem Oncology has built a differentiated pipeline of targeted therapies, including selective Rho/MRTF pathway inhibitors and focal adhesion kinase (FAK) inhibitors, which are being evaluated in various solid tumor and blood cancer settings. Ongoing clinical trials are designed to explore monotherapy activity as well as combination regimens that may overcome resistance and improve patient outcomes. Verastem Oncology conducts its clinical and translational research activities primarily in the United States, with strategic partnerships and investigator-initiated studies extending into Europe. The company collaborates with academic institutions and industry partners to accelerate the development of its pipeline assets. Verastem Oncology’s leadership team comprises experienced drug developers and oncology specialists who are committed to advancing novel therapies that address unmet medical needs in cancer treatment. AI Generated. May Contain Errors. Read More Verastem Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreVSTM MarketRank™: Verastem scored higher than 46% of companies evaluated by MarketBeat, and ranked 615th out of 863 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingVerastem has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 2 strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialVerastem has a consensus price target of $15.60, representing about 285.6% upside from its current price of $4.05.Amount of Analyst CoverageVerastem has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Verastem's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Verastem are expected to grow in the coming year, from ($1.54) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verastem is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verastem is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerastem has a P/B Ratio of 5.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Verastem's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.62% of the float of Verastem has been sold short.Short Interest Ratio / Days to CoverVerastem has a short interest ratio ("days to cover") of 10.13, which indicates bearish sentiment.Change versus previous monthShort interest in Verastem has recently increased by 18.71%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVerastem does not currently pay a dividend.Dividend GrowthVerastem does not have a long track record of dividend growth. News and Social Media1.5 / 5News SentimentN/A News SentimentVerastem has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Verastem this week, compared to 4 articles on an average week.Search InterestOnly 8 people have searched for VSTM on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Verastem to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Verastem insiders have not sold or bought any company stock.Percentage Held by Insiders1.94% of the stock of Verastem is held by insiders.Percentage Held by Institutions88.37% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verastem's insider trading history. Receive VSTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VSTM Stock News HeadlinesVSTM Stock Climbs After-Hours As FDA Grants Fast Track To Lung Cancer Drug — Retail Eyes The Next KeytrudaJune 5, 2026 | finance.yahoo.comVerastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerJune 3, 2026 | businesswire.comFree Wealth Preservation Guide Reveals How to Keep Savings Out of Washington’s ReachOver 36 trillion dollars sits in American retirement accounts - and some legal experts warn that money may not be as protected as savers assume. Greece raided private pensions. Cyprus took money directly from bank accounts. Poland nationalized retirement funds overnight. A free Wealth Defense Guide outlines what these historical precedents could mean for your IRA or 401(k).June 12 at 1:00 AM | Priority Gold (Ad)Verastem Oncology to Present at Jefferies Healthcare ConferenceMay 27, 2026 | businesswire.comVerastem Shareholders Back Board, Executive Pay and PlansMay 26, 2026 | tipranks.comVerastem IncMay 23, 2026 | money.usnews.comVerastem (VSTM) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comVerastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business UpdatesMay 8, 2026 | finance.yahoo.comSee More Headlines VSTM Stock Analysis - Frequently Asked Questions How have VSTM shares performed this year? Verastem's stock was trading at $7.72 on January 1st, 2026. Since then, VSTM shares have decreased by 47.6% and is now trading at $4.0460. How were Verastem's earnings last quarter? Verastem, Inc. (NASDAQ:VSTM) posted its earnings results on Wednesday, March, 4th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.01. The biopharmaceutical company earned $17.54 million during the quarter, compared to analyst estimates of $16.85 million. Verastem had a negative net margin of 391.17% and a negative trailing twelve-month return on equity of 486.40%. Read the conference call transcript. When did Verastem's stock split? Verastem shares reverse split on Thursday, June 1st 2023.The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did Verastem IPO? Verastem (VSTM) raised $45 million in an initial public offering (IPO) on Friday, January 27th 2012. The company issued 4,500,000 shares at $9.00-$11.00 per share. Who are Verastem's major shareholders? Verastem's top institutional shareholders include AIGH Capital Management LLC (2.28%), Exome Asset Management LLC (0.72%), Bank of America Corp DE (0.47%) and Y Intercept Hong Kong Ltd (0.39%). Insiders that own company stock include Dan Paterson, Daniel Calkins, Brian M Stuglik, Robert E Gagnon, Michael Kauffman and Paul A Bunn. View institutional ownership trends. How do I buy shares of Verastem? Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Verastem own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verastem investors own include TherapeuticsMD (TXMD), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU) and Gilead Sciences (GILD). Company Calendar Last Earnings3/04/2026Today6/12/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 10 days, VSTM's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:VSTM CIK1526119 Webwww.verastem.com Phone(781) 292-4200FaxN/AEmployees50Year Founded2010Price Target and Rating Average Price Target for Verastem$15.60 High Price Target$18.00 Low Price Target$13.00 Potential Upside/Downside+274.5%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$209.47 million Net Margins-391.17% Pretax Margin-391.17% Return on Equity-486.40% Return on Assets-91.56% Debt Debt-to-Equity Ratio0.89 Current Ratio3.04 Quick Ratio3.00 Sales & Book Value Annual Sales$30.91 million Price / Sales11.84 Cash FlowN/A Price / Cash FlowN/A Book Value$0.74 per share Price / Book5.63Miscellaneous Outstanding Shares87,870,000Free Float86,169,000Market Cap$365.98 million OptionableOptionable Beta0.27 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:VSTM) was last updated on 6/12/2026 by MarketBeat.com Staff. From Our PartnersDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredTHIS billionaire could hold your financial fate60-year Wall Street veteran Marc Chaikin is issuing an urgent warning about the billionaire behind an AI lab t...Chaikin Analytics | SponsoredThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...Behind the Markets | SponsoredTrump is positioned. Elon lights the fuse.A few days ago, while the market was bleeding, Trump posted on Truth Social, "The New Frontier of Finance is b...Crypto 101 Media | SponsoredAmerican retirees will miss THIS. Big Banks just moved in.Central banks spent $181.39 billion on physical gold in Q1 2026 alone - and more than half of 2025's central b...Cedar Gold Group | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredVWAV: Is This the Next Defense Breakout?VisionWave Holdings, Inc. (NASDAQ: VWAV) is developing a full-stack defense technology platform that integrate...Equiscreen | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
